RBM24 Suppresses the Tumorigenesis of Glioblastoma by Stabilizing LATS1 mRNA.

The ribose nucleic acid (RNA)-binding motif protein 24 (RBM24) has been recognized as a critical regulatory protein in various types of tumors. However, its specific role in glioblastoma (GBM) has not been thoroughly investigated. The objective of this study is to uncover the role of RBM24 in GBM and understand the underlying mechanism. The expression of RBM24 in GBM was initially analyzed using the Gene Expression Profiling Interactive Analysis (GEPIA). Subsequently, the RBM24 expression levels in clinical samples of GBM were examined, and the survival curves of GBM patients were plotted based on high- and low-expression levels of RBM24 using Kaplan-Meier (KM) plotter. In addition, RBM24 knockdown cell lines and overexpression vectors were created to assess the effects on proliferation, apoptosis, and invasion abilities. Finally, the binding level of RBM24 protein to LATS1 messenger RNA (mRNA) was determined by RNA immunoprecipitation (RIP) assay, and the expression levels of RBM24 and LATS1 were measured through quantitative reverse-transcriptase-polymerase chain reaction (qRT-PCR) and Western blot (WB). Our data revealed a significant decrease in RBM24 mRNA and protein levels in GBM patients, indicating that those with low RBM24 expression had a worse prognosis. Overexpression of RBM24 led to inhibited cell proliferation, reduced invasion, and increased apoptosis in LN229 and U87 cells. In addition, knocking down LATS1 partially reversed the effects of RBM24 on cell proliferation, invasion, and apoptosis in GBM cells. In vivo xenograft model further demonstrated that RBM24 overexpression reduced the growth of subcutaneous tumors in nude mice, accompanied by a decrease in Ki-67 expression and an increase in apoptotic events in tumor tissues. There was also correlation between RBM24 and LATS1 protein expression in the xenograft tumors. RBM24 functions to stabilize LATS1 mRNA, thereby inhibiting the proliferation, suppressing invasion, and promoting apoptosis in GBM cells.

A Systematic Review of Repeat Microvascular Decompression for Recurrent or Persistent Trigeminal Neuralgia.

OBJECTIVE: When conservative therapy fails, microvascular decompression (MVD) has been the preferred treatment of primary trigeminal neuralgia (TN). However, the management of recurrent or persistent TN after MVD can often be difficult. The purpose of the present systematic review was to objectively analyze and summarize the reported literature regarding the feasibility of repeat MVD. METHODS: We conducted a database search using the MEDLINE and PubMed databases until July 2020. The search terms used for title and abstract screening were as follows: "recurrent trigeminal neuralgia," "persistent trigeminal neuralgia," "repeat microvascular decompression," and "reexploration." The inclusion criteria for the systematic review were as follows: clinical studies (excluding case studies), repeat MVD treatment of TN, and studies that had recorded the pain relief outcomes, operative findings, and complications (if any). RESULTS: Of the 1771 initial results obtained, we performed a full text screening of 43 studies, and, ultimately, 19 were deemed eligible. A total of 2247 patients had undergone MVD for TN, of whom, 311 had experienced recurrence (13.84%). Of the 311 patients, 178 had undergone repeat MVD. The average pain-free interval was 27.75 months after the first MVD. The effective rate of repeat MVD was 91.66%, and 71.48% of the patients had had obvious compression found at repeat MVD. The postoperative complication rate after repeat MVD was 37.31% and was due to postoperative adhesions around the nerve and nerve injury caused by partial sensory rhizotomy. The most common complication after repeat MVD was facial numbness (21.89%), although the incidence of other complications was <5%. CONCLUSIONS: For patients with recurrent or persistent pain after MVD, the findings from our systematic review support that repeat MVD remains a feasible treatment for recurrent or persistent TN.

Beneficial effects of urine-derived stem cells on fibrosis and apoptosis of myocardial, glomerular and bladder cells.

Urine-derived stem cells (USCs) are isolated from voided urine and display high proliferative activity and multiple differentiation potentials. The applicability of USCs in the treatment of bladder dysfunction and in cell-based urological tissue engineering has been demonstrated. Whether they could serve as a potential stem cell source for the treatment of diabetes mellitus (DM) and its complications has not been investigated. Here, we report the repairing and protective effects of USCs on pancreatic islets, the myocardium, the renal glomerulus and the bladder detrusor in diabetic rat models. Type 2 diabetic rat models were induced by means of a high fat diet and intraperitoneal injection with streptozotocin. USCs isolated from voided urine were administered via tail veins. The functional changes of pancreatic islets, left ventricle, glomerulus and bladder micturition were assessed by means of insulin tolerance tests, echocardiography, urine biochemical indexes and cystometry. The histologic changes were evaluated by hematoxylin and eosin staining, Masson's trichrome staining and TUNEL staining. Treatment with USCs significantly alleviated the histological destruction and functional decline. Although the USC treatment did not decrease fasting blood glucose to a significantly different level, the fibrosis and apoptosis of the myocardium, glomerulus and detrusor were significantly inhibited. This study indicates that administration of USCs may be useful for the treatment of the complications of DM.

A novel rhodobacter sphaeroides expression system for real-time evaluation of heterologous protein expression levels.

Heterologous protein expression levels can not be evaluated in real-time by experimental procedures commonly used for most expression systems during host cell culture. Rb. sphaeroides has provided an ideal system for studying both photosynthesis and membrane development and exhibited potential as a novel expression system. We constructed the puc1BA and puc2BA mutant strain Rb. sphaeroides CQU68 and used it as a novel expression system to heterologously express proteins fused to ß-subunit of light-harvesting 2 complexes (LH2). The presence of LH2 with ß-subunit fusion proteins was spectrally detected by the LH2 typical absorption at ~800 nm and ~850 nm, and the formation of these complexes were further confirmed by SDS-PAGE and Western blot analysis. The expression levels of heterologous protein measured by SDS-PAGE and Western blot turned out to be higher as the typical spectral peak heights increase. These findings suggested that the production of the heterologous protein could be rapidly detected through the LH2 absorption at ~800 nm and ~850 nm. Moreover, the typical absorption could be used as a monitor for rapid and real-time evaluation of heterologous protein expression levels.